Onconetix Inc (ONCO)

Onconetix (ONCO) has reported substantial doubt about its ability to continue as a going concern due to recurring losses, negative operating cash flows, and reliance on external financing. For the first half of 2026, the company recorded a net loss of $7.1 million on minimal revenue and used $4.0 million in operating cash, while booking $8.6 million in goodwill impairment. Despite recent financing efforts, management acknowledges the need for additional capital to fund operations and strategic initiatives, including the commercialization of its Proclarix diagnostic product and the proposed Realbotix acquisition.

Onconetix (NASDAQ: ONCO) has filed a Form S-1 registration statement for the resale of up to 100 million shares of common stock by selling stockholders, linked to a July 2026 PIPE financing. These shares are convertible from Series F preferred stock, with an initial conversion price of $0.9767 per share. The company will not receive any proceeds from these resales and faces significant financial challenges, including substantial net losses and doubt about its ability to continue as a going concern, despite efforts to commercialize its Proclarix prostate cancer diagnostic and pursue a Realbotix share exchange.

Realbotix Corp. reported its Q3-2026 financial results, with consolidated revenue of $354,000, a decrease from the prior year, attributed to strategic repositioning and resource allocation toward Realbotix LLC. The company is advancing Realbotix LLC with new robot deployments and plans to launch an "Echo Generation One" direct-to-consumer robot line in 2026, featuring online-only sales and deposit-based reservations. Realbotix LLC is also progressing with its reverse takeover transaction with Onconetix, Inc., expected to close in Q4 2026, aiming for a Nasdaq listing to enhance market visibility and investor access.

This article provides detailed financial information for Onconetix, Inc. (ONCO), a biotechnology company focused on men's health and oncology solutions. It includes stock price data, historical performance, company overview, recent news, earnings trends, valuation measures, and comparative data with similar companies. The stock is currently trading at $0.8916, down 1.34%, with a market capitalization of $3.291 million.

This article provides an earnings forecast for Onconetix Inc (ONCO), detailing future EPS and revenue growth estimates. It includes current stock information such as its market cap and P/E TTM, and lists peer companies like Amgen Inc and Eli Lilly and Co for comparison. The financial data was updated on August 7, 2026.